TY - JOUR
T1 - Macelignan inhibits histamine release and inflammatory mediator production in activated rat basophilic leukemia mast cells
AU - Han, Young Sun
AU - Kim, Myung Suk
AU - Hwang, Jae Kwan
PY - 2012/10
Y1 - 2012/10
N2 - Type I allergy is characterized by the release of granule-associated mediators, lipidderived substances, cytokines, and chemokines by activated mast cells. To evaluate the anti-allergic effects of macelignan isolated from Myristica fragrans Houtt., we determined its ability to inhibit calcium (Ca 2+) influx, degranulation, and inflammatory mediator production in RBL-2 H3 cells stimulated with A23187 and phorbol 12-myristate 13-acetate. Macelignan inhibited Ca2+ influx and the secretion of β-hexosaminidase, histamine, prostaglandin E2, and leukotriene C4; decreased mRNA levels of cyclooxygenase-2, 5-lipoxygenase, interleukin-4 (IL-4), IL-13, and tumor necrosis factor-α; and attenuated phosphorylation of Akt and the mitogen-activated protein kinases extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase. These results indicate the potential of macelignan as a type I allergy treatment.
AB - Type I allergy is characterized by the release of granule-associated mediators, lipidderived substances, cytokines, and chemokines by activated mast cells. To evaluate the anti-allergic effects of macelignan isolated from Myristica fragrans Houtt., we determined its ability to inhibit calcium (Ca 2+) influx, degranulation, and inflammatory mediator production in RBL-2 H3 cells stimulated with A23187 and phorbol 12-myristate 13-acetate. Macelignan inhibited Ca2+ influx and the secretion of β-hexosaminidase, histamine, prostaglandin E2, and leukotriene C4; decreased mRNA levels of cyclooxygenase-2, 5-lipoxygenase, interleukin-4 (IL-4), IL-13, and tumor necrosis factor-α; and attenuated phosphorylation of Akt and the mitogen-activated protein kinases extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase. These results indicate the potential of macelignan as a type I allergy treatment.
UR - http://www.scopus.com/inward/record.url?scp=84866743424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866743424&partnerID=8YFLogxK
U2 - 10.1007/s10753-012-9490-1
DO - 10.1007/s10753-012-9490-1
M3 - Article
C2 - 22729280
AN - SCOPUS:84866743424
SN - 0360-3997
VL - 35
SP - 1723
EP - 1731
JO - Inflammation
JF - Inflammation
IS - 5
ER -